Plain-English translation of NCT06167681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called NouvNeu001 — a cell injection designed to be transplanted directly into specific areas of the brain (the putamen and striatum) using neurosurgery. Researchers want to see if this treatment is safe and whether it can help reduce Parkinson's symptoms in people whose disease has progressed to mid-to-late stages. Participants will also take anti-rejection medications for several months after the procedure to help their body accept the transplanted cells.
Standard Parkinson's treatments like medication often become less effective over time as the disease progresses. This trial exists to explore whether transplanting new cells into affected brain regions could offer a different approach — potentially slowing or improving symptoms in people who no longer respond well to current treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will undergo brain surgery to receive the NouvNeu001 cell transplant injection into both sides of your brain. After the procedure, you will take immunosuppressant medications for 24 to 36 weeks to prevent your immune system from rejecting the transplanted cells. You will attend multiple follow-up visits for testing, imaging scans, and assessments to monitor your safety and whether your Parkinson's symptoms improve. The trial involves about 40 participants across multiple research centers.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China